Early-career scientists Hye Ri Kang and Adrian Pickar have been chosen for the inaugural class of the Pfizer-NCBiotech Distinguished Postdoctoral Fellows in Gene Therapy.
Kang is a postdoc in Dwight Koeberl’s lab in pediatrics and medical genetics. Pickar is a postdoc with Charlie Gersbach’s molecular and genetic engineering lab.
They join four researchers at UNC-Chapel Hill in a two-year fellowship valued at $190,000 per scientist that will allow them to continue their work in their respective labs. Pfizer Inc. has committed $4 million to support the fellowships, which are intended to accelerate North Carolina’s expertise in gene therapy.